Gapping up
In reaction to earnings/guidance:
- DCFC +30.2% (guidance), ADMA +4.7% (guidance), SBNY +4.2%, SI +3%, BOOM +1.8% (CEO steps down; sees Q4 revs above expectations), PAC +0.7%, EDU +0.7%
Other news:
- NATI +15% (Emerson (EMR) submitted a proposal to acquire NI for $53 per share in cash at an implied enterprise value of $7.6 bln)
- IPHA +10.4% (Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology)
- CLLS +7% (Calyxt and Cibus announce the signing of a definitive merger agreement)
- ARBE +5.9% (files for $100 mln mixed securities shelf offering)
- ALKS +5% (Alkermes' nemvaleukin alfa (nemvaleukin) granted an Innovation Passport for the treatment of mucosal melanoma under the Innovative Licensing and Access Pathway by the UK Medicines and Healthcare products Regulatory Agency)
- ARQT +3% (Presents New Phase 2 Long-Term Data Showing Sustained Efficacy and Clearance for a Median of 10 Months with Roflumilast Cream)
- VTNR +2.6% (provides operational update for Q4 2022; Throughput volumes exceeded prior forecast)
- LILM +1.4% (appoints Oliver Vogelgesang as CFO)
- ERJ +1.3% (wins order for 15 new E195-E2 aircraft valued at $1.17 bln)
- CGAU +1.1% (reports Q4 gold production)
- DEO +1% (to acquire Don Papa Rum)
- CLF +1% (increasing current spot market base prices for all carbon hot rolled cold rolled and coated steel products by a minimum of $50 per net ton effective immediately with all new order)
Analyst comments:
- DNB +3% (upgraded to Buy from Neutral at BofA Securities)
- CHD +1.4% (upgraded to Outperform from Neutral at Credit Suisse)
- CDNS +1% (upgraded to Overweight from Neutral at Atlantic Equities)
